Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies.

Next Previous
Trial Profile

A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Sep 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pacritinib (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors S*BIO

    • Most Recent Events

    • 10 Dec 2013 Pooled analysis assessing outcomes in patients with no more than 100,000 platelets/microL at baseline presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 28 Jun 2013 Pooled safety results of this trial and 3 other phase I and II trials will be presented at the 18th Congress of the European Hematology Association in June 2013. Results also published in a Cell Therapeutics media release.
    • 19 Apr 2012 Actual end date Jan 2012 added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top